Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership on May 17, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.29 CNY | -0.11% |
|
+1.98% | -34.02% |
29/05 | Starry Pharma Gets China Nod for MRI Contrast Agent Injectable | MT |
28/05 | Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it has received CNY 934.979955 million in funding | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.02% | 562M | |
+61.96% | 856B | |
+38.95% | 631B | |
-3.71% | 359B | |
+14.93% | 325B | |
+9.06% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.76% | 177B | |
+2.38% | 165B |
- Stock Market
- Equities
- 603520 Stock
- News Zhejiang Starry Pharmaceutical Co.,Ltd.
- Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.